290 related articles for article (PubMed ID: 23770691)
1. A largely random AAV integration profile after LPLD gene therapy.
Kaeppel C; Beattie SG; Fronza R; van Logtenstein R; Salmon F; Schmidt S; Wolf S; Nowrouzi A; Glimm H; von Kalle C; Petry H; Gaudet D; Schmidt M
Nat Med; 2013 Jul; 19(7):889-91. PubMed ID: 23770691
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.
Ferreira V; Twisk J; Kwikkers K; Aronica E; Brisson D; Methot J; Petry H; Gaudet D
Hum Gene Ther; 2014 Mar; 25(3):180-8. PubMed ID: 24299335
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for lipoprotein lipase deficiency: working toward clinical application.
Rip J; Nierman MC; Sierts JA; Petersen W; Van den Oever K; Van Raalte D; Ross CJ; Hayden MR; Bakker AC; Dijkhuizen P; Hermens WT; Twisk J; Stroes E; Kastelein JJ; Kuivenhoven JA; Meulenberg JM
Hum Gene Ther; 2005 Nov; 16(11):1276-86. PubMed ID: 16259561
[TBL] [Abstract][Full Text] [Related]
4. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.
Haddley K
Drugs Today (Barc); 2013 Mar; 49(3):161-70. PubMed ID: 23527320
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.
Stroes ES; Nierman MC; Meulenberg JJ; Franssen R; Twisk J; Henny CP; Maas MM; Zwinderman AH; Ross C; Aronica E; High KA; Levi MM; Hayden MR; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2303-4. PubMed ID: 18802015
[No Abstract] [Full Text] [Related]
6. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.
Gaudet D; de Wal J; Tremblay K; Déry S; van Deventer S; Freidig A; Brisson D; Méthot J
Atheroscler Suppl; 2010 Jun; 11(1):55-60. PubMed ID: 20427244
[TBL] [Abstract][Full Text] [Related]
7. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.
Ross CJ; Twisk J; Meulenberg JM; Liu G; van den Oever K; Moraal E; Hermens WT; Rip J; Kastelein JJ; Kuivenhoven JA; Hayden MR
Hum Gene Ther; 2004 Sep; 15(9):906-19. PubMed ID: 15353045
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for lipoprotein lipase deficiency.
Gaudet D; Méthot J; Kastelein J
Curr Opin Lipidol; 2012 Aug; 23(4):310-20. PubMed ID: 22691709
[TBL] [Abstract][Full Text] [Related]
9. Assessing the potential for AAV vector genotoxicity in a murine model.
Li H; Malani N; Hamilton SR; Schlachterman A; Bussadori G; Edmonson SE; Shah R; Arruda VR; Mingozzi F; Wright JF; Bushman FD; High KA
Blood; 2011 Mar; 117(12):3311-9. PubMed ID: 21106988
[TBL] [Abstract][Full Text] [Related]
10. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.
Ross CJ; Twisk J; Bakker AC; Miao F; Verbart D; Rip J; Godbey T; Dijkhuizen P; Hermens WT; Kastelein JJ; Kuivenhoven JA; Meulenberg JM; Hayden MR
Hum Gene Ther; 2006 May; 17(5):487-99. PubMed ID: 16716106
[TBL] [Abstract][Full Text] [Related]
11. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients.
Carpentier AC; Frisch F; Labbé SM; Gagnon R; de Wal J; Greentree S; Petry H; Twisk J; Brisson D; Gaudet D
J Clin Endocrinol Metab; 2012 May; 97(5):1635-44. PubMed ID: 22438229
[TBL] [Abstract][Full Text] [Related]
12. NGS library preparation may generate artifactual integration sites of AAV vectors.
Cogné B; Snyder R; Lindenbaum P; Dupont JB; Redon R; Moullier P; Leger A
Nat Med; 2014 Jun; 20(6):577-8. PubMed ID: 24901560
[No Abstract] [Full Text] [Related]
13. Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors.
Kaeppel C; Beattie SG; Fronza R; van Logtenstein R; Salmon F; Schmidt S; Wolf S; Nowrouzi A; Glimm H; von Kalle C; Petry H; Gaudet D; Schmidt M
Nat Med; 2014 Jun; 20(6):578-9. PubMed ID: 24901561
[No Abstract] [Full Text] [Related]
14. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.
Scott LJ
Drugs; 2015 Feb; 75(2):175-82. PubMed ID: 25559420
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency.
Mehta N; Gilbert R; Chahal PS; Moreno MJ; Nassoury N; Coulombe N; Lytvyn V; Mercier M; Fatehi D; Lin W; Harvey EM; Zhang LH; Nazemi-Moghaddam N; Elahi SM; Ross CJD; Stanimirovic DB; Hayden MR
Hum Gene Ther; 2023 Sep; 34(17-18):927-946. PubMed ID: 37597209
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus vectors for gene therapy: more pros than cons?
Monahan PE; Samulski RJ
Mol Med Today; 2000 Nov; 6(11):433-40. PubMed ID: 11074369
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus vector integration.
Deyle DR; Russell DW
Curr Opin Mol Ther; 2009 Aug; 11(4):442-7. PubMed ID: 19649989
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
19. [Integration of AAV vectors and insertional mutagenesis].
Rossi A; Salvetti A
Med Sci (Paris); 2016 Feb; 32(2):167-74. PubMed ID: 26936174
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions.
Kassner U; Hollstein T; Grenkowitz T; Wühle-Demuth M; Salewsky B; Demuth I; Dippel M; Steinhagen-Thiessen E
Hum Gene Ther; 2018 Apr; 29(4):520-527. PubMed ID: 29641318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
